Murepavadin: a new antibiotic class in the pipeline

References

• Depuydt PO, Vandijck DM, Bekaert MA, et al. Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care. 2008;12:R142.
   PubMed Web of Science ®Google Scholar
• Martín-Loeches I, Diaz E, Vallés J. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care. 2014;20:516–524.
   PubMed Web of Science ®Google Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079–1081.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1–12.
   PubMed Web of Science ®Google Scholar
• Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. [cited 2018 Jan 2018]. Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf
   Google Scholar
• Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007;122:160–166.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator‐associated, and healthcare‐associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Dasta JF, McLaughlin TP, Mody SH, et al. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33:1266–1271.
   PubMed Web of Science ®Google Scholar
• Niederman M, Craven D, Bonten MJ, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• WHO. Report on the burden of endemic health care-associated infection worldwide. [cited 2018 Jan 2018]. Available from: http://apps.who.int/iris/bitstream/10665/80135/1/9789241501507_eng.pdf
   Google Scholar
• Ramirez-Estrada S, Borgatta B, Rello J. Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist. 2016;9:7–18.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Talbot G. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S150–170.
   PubMedGoogle Scholar
• Tumbarello M, De PG, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 2013;39:682–692.
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S81–S87.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Chastre J, Fagon JY, et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med. 2014;42:2178–2187.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European centre for disease prevention and control (ECDC) and the centers for disease control and prevention (CDC) classification of multidrug resistant organi. J Infect. 2015;70:213–222.
   PubMed Web of Science ®Google Scholar
• Luna CM, Rodriguez-Noriega E, Bavestrello L, et al. Gram-negative infections in adult intensive care units of latin america and the caribbean. Crit Care Res Pract. 2014;2014:1–12, Article ID 480463
   Google Scholar
• Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015;19:219–227.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Welte T, Wunderink RG. Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? Crit Care. 2016;20:19.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-2012). J Antimicrob Chemother. 2014;69:2713–2722.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Mendes RE, et al. Ceftazidime-Avibactam activity against multidrug-resistant pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother. 2015;59:3656–3659.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63:e61–e111.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Meunier D, Hopkins KL, et al. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-2016. J Antimicrob Chemother. 2017 Dec 8. Epub ahead of print. DOI:10.1093/jac/dkx438.
   Google Scholar
• Grupper M, Sutherland C, Nicolau DR. Multicenter evaluation of cetazidime-avibactam and cetolozane-tazobactam inhibitory activity aginst meropenem nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds. Antimicrob Agents Chemother. 2017;61:e00875–17.
   PubMed Web of Science ®Google Scholar
• Humphriesa RH, Hindlera JA, Wong-Beringerb A, et al. Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa Isolates. Antimicrob Agents Chemother. 2017;61:e01858–17.
   PubMed Web of Science ®Google Scholar
• Shortridge D, Castanheira M, Pfaller MA, et al. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: report from the PACTS antimicrobial surveillance program, 2012-2015. Antimicrob Agents Chemother. 2017;61:e00465–17.
   Web of Science ®Google Scholar
• Pfaller MA, Shortridge D, Sader HS, et al. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015). Braz J Infect Dis. 2017;21:627–637.
   PubMed Web of Science ®Google Scholar
• Shortridge D, Pfaller MA, Castanheira M, et al. Antimicrobial activity of ceftolozane-tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. Microb Drug Resist. 2017 Oct 17. doi: 10.1089/mdr.2017.0266. [Epub ahead of print].
   Google Scholar
• Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65:110–120.
   PubMed Web of Science ®Google Scholar
• Fraile-Ribot PA, Cabot G, Mulet X, et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2017 Nov 14. DOI:10.1093/jac/dkx42.
   PubMed Web of Science ®Google Scholar
• WHO. Antibacterial agents in clinical development. An analysis of the antibacterial clinical development pipeline, including tuberculosis. [cited 2018 Jan 2018]. Available from: http://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/
   Google Scholar
• Obrecht D, Bernardini F, Dale G, et al. Emerging new therapeutics against key Gram-negative pathogens. Ann Reps Med Chem. 2011;46:245–262.
   Web of Science ®Google Scholar
• Walsh CT, Wencewicz TA. Prospects for new antibiotics: a molecule-centered perspective. J Antibiot. 2014;67:7–22.
   PubMed Web of Science ®Google Scholar
• Robinson JA, Shankaramma SC, Jetter P, et al. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorg Med Chem. 2005;13:2055–2064.
   PubMed Web of Science ®Google Scholar
• Luther A, Moehle K, Chevalier E, et al. Protein epitope mimetic macrocycles as biopharmaceuticals. Curr Opin Chem Biol. 2017;38:45–51.
   PubMed Web of Science ®Google Scholar
• Urfer M, Bogdanovic J, Lo Monte F, et al. A peptidomimetic antibiotic targets outer membrane proteins and disrupts selectively the outer membrane in escherichia coli. J Biol Chem. 2016;291:1921–1932.
   PubMed Web of Science ®Google Scholar
• Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in pseudomonas aeruginosa. Science. 2010;327:1010–1013.
   PubMed Web of Science ®Google Scholar
• Werneburg M, Zerbe K, Juhas M, et al. Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics. Chembiochem. 2012;13:1767–1775.
   PubMed Web of Science ®Google Scholar
• Botos I, Majdalani N, Mayclin SJ, et al. Structural and functional characterization of the LPS transporter LptDE from gram-negative pathogens. Structure. 2016;24:965–976.
   PubMed Web of Science ®Google Scholar
• Sader HS, Biedenbach DJ, Jones RN, et al. In vitro evaluation of antimicrobiaal spectrum and determination of optimal MIC test conditions for the novel protein epitope mimetics antibiotic POL7080. 2012. P1456 2012. ECCMID, London, UK.
   Google Scholar
• Bernardini F, Müller M, Kunz G, et al. In vitro evaluation of MBCs, killing kinetics and inoculum effect of the novel Pseudomonas aeruginosa antibiotic POL7080. P1457. 2012. ECCMID, London, UK.
   Google Scholar
• Hawser S, Zampaloni C, Bernardini F, et al. Bactericidal activity and post-antibiotic effects of murepavadin (POL7080) against Pseudomonas aeruginosa. Manuscript in preparation.
   Google Scholar
• Mouton J, Melchers MJ, Teague J, et al. Pharmacokinetics and Pharmacodynamics of murepavadin (POL7080) in neutropenic mice and thigh and lung models. 2017. OS1019. ECCMID, Vienna, Austria.
   Google Scholar
• Kuhlmann O, Brealyy C, Simon S, et al. Metabolism and Excretion of the novel macrocycle Antibiotic POL7080. 2016. Poster P1307. ECCMID, Amsterdam, Netherlands.
   Google Scholar
• Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52(10):855–868.
   PubMed Web of Science ®Google Scholar
• Rink R, Arkema-Meter A, Baudoin I, et al. To protect peptide pharmaceuticals against peptidases. J Pharmacol Toxicol Methods. 2010;61(2):210–218.
   PubMed Web of Science ®Google Scholar
• Wach A, Sennhauser J, Kern P et al. Catabolism and excretion of the anti-pseudomonal antibiotic murepavadin (POL7080) in humans. 2017, Poster P1309. ECCMID, Vienna, Austria.
   Google Scholar
• Douglas GJ, Klukovits A, Nagy E, et al. In vitro drug transporter interaction studies with the outer membrane protein targeting antibiotic murapevadin (POL7080). 2017. Poster P1310. ECCMID, Vienna, Austria.
   Google Scholar
• Dembowsky K, Wilbraham D, Ograbek A, et al. Phase I (multiple ascending dose) study with the novel Pseudomonas aeruginosa antibiotic POL7080 in healthy volunteers. Poster P1421. 2012. ECCMID, London, United Kingdom.
   Google Scholar
• Winter E, Boetsch C, Brennan B, et al. Penetration of POL7080/RO7033877 into epithelial lining fluid and alveolar macrophages of healthy volunteers. 2015. Presented. Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy. San Diego, USA.
   Google Scholar
• Halabi A, Petersen-Sylla M, Wach A, et al. Phamacokinetics and safety of POL7080 in subjects with impaired renal function. 2016. Poster P1308. ECCMID, Amsterdam, Netherlands.
   Google Scholar
• Armaganidis A, Zakynthinos S, Mandragos C et al. Efficacy of murepavadin coadministered with standard of care in a phase 2 study in patients with ventilator-associated pneumonia due to suspected or documented pseudomonas areruginosa infection. 2017. Poster A459. ISICEM, Brussels, Belgium.
   Google Scholar
• O’Neil J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. [cited 2018 Jan 2018]. Available from: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
   Google Scholar
• Koleff MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator associated pneumonia. Chest. 2006;129:1210–1218.
   PubMed Web of Science ®Google Scholar
• Muscedere JG, Shorr AF, Jiiang X, et al. The adequacy of timely emperic antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care. 2102;27:322 e7–14.
   Google Scholar